Nomad Bioscience GmbH was awarded two significant grants from Investment Bank Saxony-Anhalt (Investitionsbank Sachsen-Anhalt) for development of griffithsin and other plant-derived lectins as preventative therapies against coronaviruses. Lectins are sugar-binding proteins some of which effectively prevent attachment of enveloped viruses (such as coronaviruses, influenza viruses, immunodeficiency viruses) to human cells thus preventing viral infection. The […]
Read MoreAutor: Firma Nomad Bioscience
NOMAD Bioscience Published Milestone Paper in Nature Plants Describing its RNA-Based Rapid Transient Reprogramming of Crop Plants for Agronomic Performance
NOMAD Bioscience announces the publication in Nature Plants (Torti et al. (2021) Nature Plants 7; https://www.nature.com/articles/s41477-021-00851-y) a research paper describing NOMAD’s novel transient RNA replicon-based process of controlling agronomic performance of crop plants. The process does not involve genetic modification of the plant genome and is thus limited to a single plant generation, is broadly […]
Read MoreNOMAD Bioscience Receives Its GRAS Regulatory Clearance In USA For Plant-Made Natural Thaumatin II As Flavour Modifier
NOMAD Bioscience GmbH received a formal ‘no questions’ letter from the US Food and Drug Administration (FDA) in response to NOMAD’s GRAS notice GRN 920 describing use of plant-produced Thaumatin II as flavour modifier. Thaumatin II is natural non-caloric high intensity sweetener and flavour modifier under development at NOMAD. GRAS is a facilitated US regulatory […]
Read MoreNOMAD BIOSCIENCE Enters Into Agreement with CTAEX, Spain, To Conduct Its First Field Trials With Plants Producing Non-Caloric Sweetener Thaumatin II in Extremadura, Spain
NOMAD BIOSCIENCE GmbH, Munich, Germany (“NOMAD”) is pleased to announce that it has entered into a research and development agreement with CENTRO TECNOLOGICO NACIONAL AGROALIMENTARIO EXTREMADURA (“CTAEX”), Badajoz, Spain. In accordance with the Agreement, CTAEX is expected to conduct in 2021 first open field trials with NOMAD plant hosts expressing Thaumatin II, a natural high-intensity […]
Read MoreNOMADS UAB, Lithuania, Receives a Research Grant from Lithuanian Business Support Agency LVPA
NOMADS UAB, Vilnius, Lithuania (“NOMADS”), a wholly owned subsidiary of Nomad Bioscience GmbH, Munich, Germany, is pleased to announce that the Company has been awarded a research grant from LVPA (Lietuvos Verslo Paramos Agentūra, Lithuanian Business Support Agency) to extend its exploration of antibacterial proteins for control of multi-drug and pan-drug resistant pathogenic bacteria Klebsiella and […]
Read MoreNOMAD Bioscience Receives Its GRAS Regulatory Clearance In USA For Plant-Made Natural Thaumatin II As Sweetener
NOMAD Bioscience received a formal ‘no questions’ letter from the US Food and Drug Administration (FDA) in response to NOMAD’s GRAS notice GRN 910 describing use of plant-produced Thaumatin II as sweetener. Thaumatin II is natural noncaloric high intensity sweetener under development at NOMAD. GRAS is a facilitated US regulatory marketing allowance pathway for food […]
Read MoreNomad Bioscience and Fraunhofer Institute for Cell Therapy and Immunology Enter into a Research and Development Agreement
Nomad Bioscience GmbH (“NOMAD”) is pleased to announce that the Company has entered into a broad research and development agreement with the Department of Drug Design and Target Validation of the Fraunhofer Institute for Cell Therapy and Immunology (Fraunhofer IZI), headquartered in Leipzig, Germany. The agreement covers multiple areas of research and early development of NOMAD’s R&D […]
Read More